Insider · CIK 0001820278
Denice Torres
Files at CLDX (Celldex Therapeutics, Inc.), GKOS (GLAUKOS Corp), TSVT (2seventy bio, Inc.). First filing -, latest -.
Denice Torres files SEC Form 4 as director at CLDX (Celldex Therapeutics, Inc.), and also at GKOS (GLAUKOS Corp), TSVT (2seventy bio, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Denice Torres has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | CLDX Celldex Therapeutics, Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +26,000 | $0.00 | $0 | 26,000 | Jun 29, 2026 |
| May 28, 2026 | GKOS GLAUKOS Corp | AGrant or award Common Stock | +1,878 | $0.00 | $0 | 24,212 | Jun 1, 2026 |
| May 28, 2026 | GKOS GLAUKOS Corp | AGrant or award Stock Option (Right to Buy)derivative | +2,987 | $0.00 | $0 | 2,987 | Jun 1, 2026 |
| Jan 2, 2026 | GKOS GLAUKOS Corp | AGrant or award Common Stock | +623 | $0.00 | $0 | 22,334 | Jan 7, 2026 |
| Jun 5, 2025 | CLDX Celldex Therapeutics, Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +33,000 | $0.00 | $0 | 33,000 | Jun 9, 2025 |
| Jan 2, 2025 | GKOS GLAUKOS Corp | AGrant or award Common Stock | +461 | $0.00 | $0 | 19,603 | Jun 2, 2025 |
| May 29, 2025 | GKOS GLAUKOS Corp | AGrant or award Common Stock | +2,108 | $0.00 | $0 | 21,711 | Jun 2, 2025 |
| May 29, 2025 | GKOS GLAUKOS Corp | AGrant or award Stock Option (Right to Buy)derivative | +3,149 | $0.00 | $0 | 3,149 | Jun 2, 2025 |
| May 13, 2025 | TSVT 2seventy bio, Inc. | DDisposition to issuer Common Stock | -12,050 | - | - | 19,510 | May 15, 2025 |
| May 13, 2025 | TSVT 2seventy bio, Inc. | UTender of shares Common Stock | -19,510 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | TSVT 2seventy bio, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -24,100 | - | - | 0 | May 15, 2025 |
Questions about Denice Torres
Answered from the filings on this page, as of the latest one.
Is Denice Torres buying or selling?
Denice Torres has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Denice Torres's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Denice Torres has 0.
Where does Denice Torres file Form 4?
Denice Torres has filed Form 4 at CLDX (Celldex Therapeutics, Inc.); GKOS (GLAUKOS Corp); TSVT (2seventy bio, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.